Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial

被引：1

作者：

Oliva, Esther Natalie ^{[1
]}

Santini, Valeria ^{[2
]}

Alati, Caterina ^{[1
]}

Poloni, Antonella ^{[3
]}

Molteni, Alfredo ^{[4
]}

Niscola, Pasquale ^{[5
]}

Sanpaolo, Grazia ^{[6
]}

Salvi, Flavia ^{[7
]}

Palumbo, Giuseppe A. ^{[8
]}

Balleari, Enrico ^{[9
]}

Impera, Stefana ^{[10
]}

Cortelezzi, Agostino ^{[11
]}

Liberati, Anna Marina ^{[12
]}

Avanzini, Paolo ^{[13
]}

Di Bartolomeo, Paolo ^{[14
]}

Rose, Christian ^{[15
]}

Beyne-Rauzy, Odile ^{[16
]}

Buccisano, Francesco ^{[17
]}

Bocchia, Monica ^{[18
]}

Morabito, Fortunato ^{[19
]}

Stamatoullas, Aspasia ^{[20
]}

Ronco, Francesca ^{[1
]}

Zini, Gina ^{[21
]}

D'Errigo, Maria Grazia ^{[22
]}

Ranieri, Natale ^{[1
]}

Cufari, Patrizia ^{[1
]}

Santacaterina, Irene ^{[1
]}

Fenaux, Pierre ^{[23
]}

Latagliata, Roberto ^{[24
]}

机构：

[1] Azienda Osped Bianchi Melacrino Morelli, Hematol, Reggio Di Calabria, Italy

[2] Univ Florence, AOU Careggi, Florence, Italy

[3] Osped Riuniti Ancona, Haematol Clin, Ancona, Italy

[4] Osped Niguarda Ca Granda, Milan, Italy

[5] S Eugenio Hosp, Dept Hematol, Rome, Italy

[6] Ist Casa Sollievo Sofferenza, Hematol, San Giovanni Rotondo, Italy

[7] SS Antonio & Biagio Hosp, Hematol, Alessandria, Italy

[8] Univ Catania, Div Hematol, Osped Ferrarotto, Catania, Italy

[9] Genova Hosp, Genoa, Italy

[10] ARNAS Garibaldi Nesima, Sect Hematol, Catania, Italy

[11] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Oncohematol Unit, Milan, Italy

[12] Azienda Osped S Maria, SC Oncoematol, Terni, Italy

[13] Santa Maria Nuova Hosp, Hematol, Reggio Emilia, Italy

[14] Osped Civile Santo Spirito, Dipartimento Ematol, Pescara, Italy

[15] Hop St Vincent, Dept Hematol, Lille, France

[16] CHU Purpan, Serv Med Interne, Toulouse, France

[17] Univ Roma Tor Vergata, Hematol, Rome, Italy

[18] Univ Siena, Dept Hematol & Transplants, I-53100 Siena, Italy

[19] AO Annunziata Cosenza, Sect Hematol, Cosenza, Italy

[20] Ctr Henri Becquerel, Clin Hematol, F-76038 Rouen, France

[21] Univ Cattolica Sacro Cuore, Hematol, Ctr Ric ReCAMH, I-00168 Rome, Italy

[22] Azienda Osped Bianchi Melacrino Morelli, Genet Lab, Reggio Di Calabria, Italy

[23] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France

[24] Univ Roma La Sapienza, Div Hematol, Dept Cellular Biotechnol & Hematol, I-00185 Rome, Italy

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
Platzbecker, U.
Germing, U.
Giagounidis, A.
Goetze, K.
Kiewe, P.
Mayer, K.
Ottmann, O.
Radsak, M.
Wolff, T.
Haase, D.
Hankin, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M.
Attie, K.
[J]. LEUKEMIA RESEARCH, 2015, 39 : S25 - S25
[42] Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Platzbecker, Uwe
Steensma, David P.
Van Eygen, Koen
Raza, Azra
Santini, Valeria
Germing, Ulrich
Font, Patricia
Diez-Campelo, Maria
Thepot, Sylvain
Vellenga, Edo
Patnaik, Mrinal M.
Jang, Jun Ho
Sherman, Laurie
Dougherty, Souria
Feller, Faye
Sun, Libo
Wan, Ying
Huang, Fei
Rizo, Aleksandra
Fenaux, Pierre
[J]. BLOOD, 2019, 134
[43] Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia
Giagounidis, Aristoteles
Mufti, Ghulam J.
Fenaux, Pierre
Sekeres, Mikkael A.
Szer, Jeffrey
Platzbecker, Uwe
Kuendgen, Andrea
Gaidano, Gianluca
Wiktor-Jedrzejczak, Wieslaw
Hu, Kuolung
Woodard, Paul
Yang, Allen S.
Kantarjian, Hagop M.
[J]. CANCER, 2014, 120 (12) : 1838 - 1846
[44] BIOSIMILAR EPOETIN IN ELDERLY PATIENTS WITH LOW-RISK/INTERMEDIATE 1 MYELODYSPLASTIC SYNDROMES IMPROVES ANEMIA, QUALITY OF LIFE AND BRAIN FUNCTION
Castelli, R.
Deliliers, G. Lambertenghi
Colombo, R.
Gallipoli, P.
Pantaleo, G.
[J]. HAEMATOLOGICA, 2014, 99 : 616 - 616
[45] ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study
Platzbecker, Uwe
Germing, Ulrich
Giagounidis, Aristoteles
Goetze, Katharina
Kiewe, Philipp
Mayer, Karin
Ottman, Oliver
Radsak, Markus P.
Wolff, Thomas
Haase, Detlef
Hankin, Monty
Wilson, Dawn M.
Laadem, Adberrahmane
Sherman, Matthew L.
Attie, Kenneth M.
[J]. BLOOD, 2014, 124 (21)
[46] Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial
Revicki, Dennis A.
Brandenburg, Nancy A.
Muus, Petra
Yu, Ren
Knight, Robert
Fenaux, Pierre
[J]. LEUKEMIA RESEARCH, 2013, 37 (03) : 259 - 265
[47] Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"
Sebert, Marie
Chaffaut, Cendrine
Thepot, Sylvain
Orvain, Corentin
Cluzeau, Thomas
Loschi, Michael
Peterlin, Pierre
Chevallier, Patrice
d'Aveni, Maud
Rubio, Marie-Therese
Rauzy, Odile Beyne
Huynh, Anne
Charbonnier, Amandine
Fegueux, Nathalie
Fossard, Gaelle
N'guyen-Quoc, Stephanie
Park, Sophie
Sapena, Rosa
Chermat, Fatiha
Ades, Lionel
Chevret, Sylvie
Fenaux, Pierre
Robin, Marie
[J]. BLOOD, 2021, 138 : 1842 - +
[48] Treatment of transfusional iron overload with deferasirox in patients with low and intermediate-1 risk MDS: Results from a German multi-center trial
Nolte, F.
Hoechsmann, B.
Luebbert, M.
Platzbecker, U.
Haase, D.
Lueck, A.
Gattermann, N.
Giagounidis, A.
May, C.
Leismann, O.
Junkes, A.
Schumann, C.
Hofmann, W. -K
Schrezenmeier, H.
[J]. ONKOLOGIE, 2011, 34 : 290 - 290
[49] Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial
Garcia-Manero, Guillermo
Yee, Karen W. L.
Hernandez, Francisca
Della Porta, Matteo Giovanni
Paolini, Stefania
Ahn, Seo-Yeon
Santini, Valeria
Fenaux, Pierre
Suzuki, Takahiro
Sekeres, Mikkael A.
He, Jun
Li, Jerry
Barkalifa, Ronit
Vigil, Carlos E.
Prebet, Thomas
de Menezes, Daniel Lopes
Burnett, Joseph
Komrokji, Rami S.
Giagounidis, Aristoteles
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
Lyons, Roger M.
Larson, Richard A.
Kosmo, Michael A.
Gandhi, Sunil
Liu, Delong
Chernoff, Marc
Dreisbach, Luke
Matei, Carmen
Hu, Kuolong
Franklin, Janet L.
Berger, Dietmar
[J]. BLOOD, 2009, 114 (22) : 703 - 704

← 1 2 3 4 5 →